Richard Peters insider trades

Open-market stock purchases and sales by Richard Peters, Director at Aprea Therapeutics, Inc, from SEC Form 4 filings since Jun 6, 2017.

Track record: 0% of 1 scored buy are up 5% or more since purchase, averaging -21%.

Recent trades

DateStockTradeValue
Jun 16, 2026APRE Aprea Therapeutics, IncBought (not open market)—
Jun 16, 2026APRE Aprea Therapeutics, IncBought (not open market)—
Mar 31, 2026APRE Aprea Therapeutics, IncBought$84.6K

Companies traded

  • APRE Aprea Therapeutics, Inc: 1 buy, last Jun 16, 2026
  • KANT Kineta, Inc./de: other filings, last Jun 30, 2025
  • KA Kineta, Inc./de: other filings, last Sep 4, 2024
  • YMTX Yumanity Therapeutics, Inc: 4 sales, last Dec 2, 2022
  • MACK Merrimack Pharmaceuticals Inc: other filings, last May 8, 2019

Get free alerts when Richard Peters files a new trade →